Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Solid Tumors

Ongoing, but not recruiting

1

Start Date 11/01/2011

Age of Trial (yrs) 13.1

Gleevec-resistant

AKT inhibitor

Block AKT

GIST not specified. GIST patient enrollment unknown.

ARQ 092-101

ArQule

ArQule, Inc 781-994-0300 ClinicalTrials@arqule.com

Oral

Purpose
This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors and recurrent malignant lymphoma. The study is designed to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ 092 and to define a recommended Phase 2 dose of ARQ 092.